| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Vicki Stone | Q35851438 |
| P2093 | author name string | Peter Møller | |
| Ali Kermanizadeh | |||
| Leagh G Powell | |||
| P2860 | cites work | Recovery of Cognitive Dysfunction via Orally Administered Redox-Polymer Nanotherapeutics in SAMP8 Mice | Q27308007 |
| Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study | Q28551006 | ||
| A new family of nonsiliceous porous hybrids from bisphosphonates | Q30647420 | ||
| Effective mucoadhesive liposomal delivery system for risedronate: preparation and in vitro/in vivo characterization | Q33633359 | ||
| Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles | Q33683206 | ||
| Luminescent/magnetic PLGA-based hybrid nanocomposites: a smart nanocarrier system for targeted codelivery and dual-modality imaging in cancer theranostics | Q33807175 | ||
| Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs | Q34011214 | ||
| Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects | Q34030709 | ||
| Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles | Q34065947 | ||
| Nanopharmaceuticals (part 1): products on the market | Q34230175 | ||
| Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and in vivo absorption | Q34377929 | ||
| Assembled nanomedicines as efficient and safe therapeutics for articular inflammation | Q84991829 | ||
| The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles | Q85654843 | ||
| Cellular mechanism of oral absorption of solidified polymer micelles | Q85746515 | ||
| Gastrointestinal Motility Variation and Implications for Plasma Level Variation: Oral Drug Products | Q86952944 | ||
| G5 PAMAM dendrimer versus liposome: a comparison study on the in vitro transepithelial transport and in vivo oral absorption of simvastatin | Q86961821 | ||
| Natural lipids enriched self-nano-emulsifying systems for effective co-delivery of tamoxifen and naringenin: Systematic approach for improved breast cancer therapeutics | Q87670935 | ||
| Nanoassembly of probucol enables novel therapeutic efficacy in the suppression of lung metastasis of breast cancer | Q88082644 | ||
| Mucosal transfer of wheat germ agglutinin modified lipid-polymer hybrid nanoparticles for oral delivery of oridonin | Q88139046 | ||
| GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner | Q90024201 | ||
| Advances in understanding the role of cytokines in inflammatory bowel disease | Q90338139 | ||
| Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy. | Q50683194 | ||
| Integrin Targeting and Toxicological Assessment of Peptide-Conjugated Liposome Delivery Systems to Activated Endothelial Cells. | Q51130308 | ||
| Different inflammatory response and oxidative stress in neointimal hyperplasia after balloon angioplasty and stent implantation in cholesterol-fed rabbits. | Q51219643 | ||
| Management of Hypersensitivity Reactions to Taxanes. | Q53830532 | ||
| Oral Particle Uptake and Organ Targeting Drives the Activity of Amphotericin B Nanoparticles | Q57610399 | ||
| A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary | Q59705984 | ||
| A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1 | Q34426261 | ||
| In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation | Q34708906 | ||
| Optical imaging of absorption and distribution of RITC-SiO2 nanoparticles after oral administration | Q34787869 | ||
| Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: in vitro and in vivo evaluations | Q35766431 | ||
| Pharmacokinetics, tissue distribution, and metabolites of a polyvinylpyrrolidone-coated norcantharidin chitosan nanoparticle formulation in rats and mice, using LC-MS/MS. | Q35972507 | ||
| Progress and future of in vitro models to study translocation of nanoparticles. | Q36001471 | ||
| Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation | Q36119605 | ||
| Solid lipid nanoparticles modified with stearic acid-octaarginine for oral administration of insulin | Q36119610 | ||
| Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy | Q36161416 | ||
| Biological and therapeutic activities, and anticancer properties of curcumin | Q36334519 | ||
| Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action. | Q36356343 | ||
| Liposomes coated with N-trimethyl chitosan to improve the absorption of harmine in vivo and in vitro | Q36498718 | ||
| Targeted modulation of cell differentiation in distinct regions of the gastrointestinal tract via oral administration of differently PEG-PEI functionalized mesoporous silica nanoparticles. | Q36498783 | ||
| Enhanced oral absorption of 20(S)-protopanaxadiol by self-assembled liquid crystalline nanoparticles containing piperine: in vitro and in vivo studies | Q36620613 | ||
| Nanotechnology inspired tools for mitochondrial dysfunction related diseases | Q36703351 | ||
| Clinical toxicities of nanocarrier systems | Q37099798 | ||
| Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex | Q37234697 | ||
| Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation. | Q37474599 | ||
| Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake | Q37490613 | ||
| Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats | Q37602960 | ||
| Fabrication and in vitro/in vivo evaluation of amorphous andrographolide nanosuspensions stabilized by d-α-tocopheryl polyethylene glycol 1000 succinate/sodium lauryl sulfate | Q37638743 | ||
| Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract | Q37680163 | ||
| Lipid-based nanocarriers as an alternative for oral delivery of poorly water- soluble drugs: peroral and mucosal routes. | Q38029748 | ||
| Investigating the relationship between nanomaterial hazard and physicochemical properties: Informing the exploitation of nanomaterials within therapeutic and diagnostic applications | Q38039780 | ||
| Determinants of carbon nanotube toxicity. | Q38127559 | ||
| Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics | Q38275513 | ||
| Oral bioavailability: issues and solutions via nanoformulations | Q38349734 | ||
| Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics | Q38495022 | ||
| Challenges in oral peptide delivery: lessons learnt from the clinic and future prospects | Q38653884 | ||
| A Flow Cytometry-based Method for the Screening of Nanomaterial-induced Reactive Oxygen Species Production in Leukocytes Subpopulations in Whole Blood | Q38660448 | ||
| Comparisons of the biodistribution and toxicological examinations after repeated intravenous administration of silver and gold nanoparticles in mice. | Q38728758 | ||
| Involvement of Drug Transporters in Organ Toxicity: The Fundamental Basis of Drug Discovery and Development. | Q38738599 | ||
| Overview on gastroretentive drug delivery systems for improving drug bioavailability | Q38833183 | ||
| Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. | Q38834450 | ||
| Metabolic fate of poly-(lactic-co-glycolic acid)-based curcumin nanoparticles following oral administration | Q38841668 | ||
| Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: Systematic development, in vitro, ex vivo and in vivo evaluation | Q38849229 | ||
| Oral uptake of nanoparticles: human relevance and the role of in vitro systems | Q38876253 | ||
| Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. | Q39096113 | ||
| Disruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanisms | Q39189861 | ||
| Protein corona: a new approach for nanomedicine design | Q39274203 | ||
| A review of drug release mechanisms from nanocarrier systems. | Q39291234 | ||
| Brain-targeted polymeric nanoparticles: in vivo evidence of different routes of administration in rodents | Q39438422 | ||
| Combination anti-HIV therapy with the self-assemblies of an asymmetric bolaamphiphilic zidovudine/didanosine prodrug. | Q39546080 | ||
| Lipid-based oral delivery systems for skin deposition of a potential chemopreventive DIM derivative: characterization and evaluation | Q39609219 | ||
| Nanostructured nanoparticles of self-assembled lipid pro-drugs as a route to improved chemotherapeutic agents | Q39617653 | ||
| Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies | Q39690385 | ||
| Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization | Q39841366 | ||
| The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis | Q39940223 | ||
| New perspectives in nanotherapeutics for chronic respiratory diseases. | Q40039105 | ||
| Formulation design space: a proven approach to maximize flexibility and outcomes within early clinical development | Q40283164 | ||
| Toxicity evaluation of zinc aluminium levodopa nanocomposite via oral route in repeated dose study | Q40412017 | ||
| Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes | Q41184651 | ||
| Styrene maleic acid encapsulated raloxifene micelles for management of inflammatory bowel disease | Q41219004 | ||
| Mechanism of enhanced oral absorption of hydrophilic drug incorporated in hydrophobic nanoparticles | Q41854707 | ||
| Biocompatible nanoemulsions based on hemp oil and less surfactants for oral delivery of baicalein with enhanced bioavailability | Q42291604 | ||
| Targeted cancer therapy with novel high drug-loading nanocrystals | Q43011647 | ||
| In vitro and in vivo studies of lipid-based nanocarriers for oral N3-o-toluyl-fluorouracil delivery | Q43101389 | ||
| Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice | Q43623067 | ||
| Pluronic P85/poly(lactic acid) vesicles as novel carrier for oral insulin delivery | Q44373183 | ||
| Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies | Q45268731 | ||
| Oleanolic acid nanosuspensions: preparation, in-vitro characterization and enhanced hepatoprotective effect | Q45273790 | ||
| Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs | Q45339496 | ||
| Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation | Q46448056 | ||
| In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems | Q46460642 | ||
| Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method. | Q46907206 | ||
| Oridonin synergistically enhances JQ1-triggered apoptosis in hepatocellular cancer cells through mitochondrial pathway | Q47128815 | ||
| Inhibition of Notch signaling pathway using γ-secretase inhibitor delivered by a low dose of Triton-X100 in cultured oral cancer cells | Q47239134 | ||
| Assessment of genotoxicity and biodistribution of nano- and micron-sized yttrium oxide in rats after acute oral treatment. | Q47706741 | ||
| Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy. | Q47718781 | ||
| Disorders of Mechanisms of Calcium Metabolism Control as Potential Risk Factors of Prostate Cancer. | Q47812485 | ||
| Pharmacokinetic Consequences of PLGA Nanoparticles in Docetaxel Drug Delivery | Q47869974 | ||
| Comparative evaluation of proliposomes and self micro-emulsifying drug delivery system for improved oral bioavailability of nisoldipine | Q47877489 | ||
| Development of Yam Dioscorin-Loaded Nanoparticles for Paracellular Transport Across Human Intestinal Caco-2 Cell Monolayers. | Q48253836 | ||
| Suppression of NSAID-induced small intestinal inflammation by orally administered redox nanoparticles. | Q48444628 | ||
| Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics | Q50226473 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanoparticle | Q61231 |
| biophysics | Q7100 | ||
| bioengineering | Q580689 | ||
| drug discovery | Q1418791 | ||
| manufactured product | Q3406743 | ||
| drug delivery system | Q64829245 | ||
| pharmaceutical preparation | Q66089252 | ||
| P304 | page(s) | 7575-7605 | |
| P577 | publication date | 2018-01-01 | |
| 2018-11-16 | |||
| P1433 | published in | International Journal of Nanomedicine | Q6051502 |
| P1476 | title | Nanodelivery systems and stabilized solid-drug nanoparticles for orally administered medicine: current landscape | |
| P478 | volume | 13 |
| Q92662151 | Analysis of the Exposure of Organisms to the Action of Nanomaterials |
| Q87129139 | Assessment of nanomaterial-induced hepatotoxicity using a 3D human primary multi-cellular microtissue exposed repeatedly over 21 days - the suitability of the in vitro system as an in vivo surrogate |
| Q90573359 | Critical Role of B Cells in Toll-Like Receptor 7-Mediated Protection against Listeria monocytogenes Infection |
| Q60916945 | Exploiting PLGA-Based Biocompatible Nanoparticles for Next-Generation Tolerogenic Vaccines against Autoimmune Disease |
| Q89475322 | Lipid-based nanoparticles in the treatment of erectile dysfunction |
| Q93054853 | Nanodelivery of Natural Antioxidants: An Anti-aging Perspective |
| Q109729000 | Particulate and drug-induced toxicity assessed in novel quadruple cell human primary hepatic disease models of steatosis and pre-fibrotic NASH |
| Q64115917 | Role of nanostructures in improvising oral medicine |
| Q64057451 | The importance of inter-individual Kupffer cell variability in the governance of hepatic toxicity in a 3D primary human liver microtissue model |
Search more.